Kevin Nilles

Kevin Nilles serves as a Contracting Officer responsible for managing complex acquisitions in the biomedical and scientific research sectors. He plays a critical role in executing the agency’s procurement mission by ensuring compliance with federal acquisition regulations while fostering innovation through competitive, transparent contracting practices. His portfolio primarily consists of requirements related to biological product manufacturing, biotechnology research and development, and specialized scientific consulting services. Nilles is experienced in navigating the intricacies of FAR Part 19 socioeconomic programs and routinely engages with industry stakeholders to align procurement strategies with national health and scientific priorities. While specific contractor names are not available, Nilles maintains a broad network of vendors specializing in life sciences and technical consulting, including both large prime contractors and niche research firms. His contracting approach emphasizes performance-based outcomes, clear statement of work development, and risk mitigation through rigorous source selection processes. He frequently collaborates with technical evaluators and program managers to ensure acquisitions meet mission-critical standards for quality, safety, and regulatory compliance. Nilles demonstrates a strong preference for open competition, with 92.9% of his awards issued without set-aside restrictions. However, he consistently supports small business participation, allocating 7.1% of his contracts to Total Small Business Set-Asides under FAR 19.5. This reflects a deliberate, measured commitment to expanding opportunities for small businesses without compromising acquisition efficiency or mission readiness. His primary procurement focus lies in NAICS 325414 (Biological Product Manufacturing), 541714 (Biotechnology R&D), and 541690 (Scientific Consulting Services). He regularly procures advanced therapeutics, laboratory-developed biologicals, and specialized research services requiring compliance with FDA, CDC, or NIH standards. His technical expertise spans biopharmaceutical development pipelines, clinical trial support systems, and translational research infrastructure, positioning him as a key liaison between federal science objectives and industry innovation.